Trials / Unknown
UnknownNCT04887025
Exploratory Study of a Novel Oncolytic Vaccinia Virus RGV004 in the Treatment of Refractory/Relapsed B-cell Lymphoma
Exploratory Study of a Novel Oncolytic Vaccinia Virus Expressing Bispecific Antibody in the Treatment of Refractory/Relapsed B-cell Lymphoma
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a dose-escalation, single-arm, single-center open study which aims to evaluate the maximum tolerated dose (MTD) and dose-dependent toxicity (DLT) of a novel oncolytic vaccinia virus expressing bispecific antibody RGV004 in patients with relapsed/refractory B-cell lymphoma,
Detailed description
Oncolytic vaccinia virus administered by intratumoral injection
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | RGV004 | a genetically-engineered vaccinia virus (encoding CD19/CD3 bispecific antibody) |
Timeline
- Start date
- 2022-02-08
- Primary completion
- 2023-03-15
- Completion
- 2025-03-15
- First posted
- 2021-05-14
- Last updated
- 2023-02-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04887025. Inclusion in this directory is not an endorsement.